Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data

F. Palandri, M. Breccia, M. Tiribelli, M. Bonifacio, G. Benevolo, A. Iurlo, E.M. Elli, G. Binotto, A. Tieghi, N. Polverelli, B. Martino, E. Abruzzese, M. Bergamaschi, F.H. Heidel, F. Cavazzini, M. Crugnola, C. Bosi, A. Isidori, G. Auteri, D. ForteR. Latagliata, D. Griguolo, D. Cattaneo, M. Trawinska, D. Bartoletti, M. Krampera, G. Semenzato, R.M. Lemoli, A. Cuneo, F. Di Raimondo, N. Vianelli, M. Cavo, G.A. Palumbo

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data'. Together they form a unique fingerprint.

Medicine & Life Sciences